Skip to main content Accessibility help
×
Home

Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

  • K. E. CHAPMAN (a1), D. WILSON (a2) and R. GORTON (a1)

Summary

The 7-valent pneumococcal conjugate vaccine (PCV7) has been included in the routine childhood immunization programme in the UK since September 2006. A population-based study of serotypes causing invasive pneumococcal disease (IPD) post-PCV7 in North East England was conducted using data from a regional enhanced IPD surveillance system. Overall, there was a 20% reduction [95% confidence interval (CI) 5–32] from 12·1 cases/100 000 population in 2006/2007 to 9·7 in 2009/2010. There was a fall in IPD caused by PCV7 serotypes in all age groups, with reductions of 90% (95% CI 61–99) in children aged <5 years, 50% (95% CI 4–75) in persons aged 5–64 years and 66% (95% CI 40–82) in adults aged ⩾65 years. There was a non-significant increase in IPD caused by non-PCV7 serotypes in children aged <5 years of 88% (95% CI −10 to 312) and adults aged ⩾65 years of 12% (95% CI −19 to 50), which was largely caused by serotypes 7F, 19A and 22F. Replacement disease appears to have reduced the benefits of PCV7 in North East England.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Dr K. E. Chapman, Health Protection Agency North East, North East Regional Epidemiology Unit, Floor 2, Citygate, Gallowgate, Newcastle upon Tyne, NE1 4WH, UK. (Email: kaye.chapman@hpa.org.uk)

References

Hide All
1.Hausdorff, WP, Feikin, DR, Klugman, KP. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005; 5: 8393.
2.Brueggemann, AB, et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. Journal of Infectious Diseases 2003; 187: 14241432.
3.Sandgren, A, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. Journal of Infectious Diseases 2004; 189: 785796.
4.Pilishvili, T, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010; 201: 3241.
5.Centres for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. Morbidity and Mortality Weekly Report 2005; 54: 893897.
6.Lexau, CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. Journal of the American Medical Association 2005; 294: 20432051.
7.World Health Organisation. Worldwide progress in introducing pneumococcal conjugate vaccine, 2000–2008. Weekly Epidemiological Record 2008; 43: 388392.
8.Department of Health. Immunization against infectious disease. The Green Book 2010; 25: 295313.
9.Health Protection Agency. Quarterly vaccination coverage statistics for children aged up to five years in the UK (COVER programme): October to December 2007. Health Protection Report 2008; 2: 13 (http://www.hpa.org.uk/hpr/archives/2008/hpr1308.pdf).
10.Director of Immunization, Department of Health. Introduction of Prevenar 13® into the childhood immunization programme, 2010 (http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_112192.pdf). Accessed 31 August 2011.
11.Office for National Statistics. United Kingdom: Health geography, as at 1 July 2006 (http://www.statistics.gov.uk/geography/downloads/HLTH_JUL_2006%20_UK_MP.pdf). Accessed 31 August 2011.
12.Miller, E, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases 2011; 11: 760768.
13.Health Protection Agency. Current epidemiology of invasive pneumococcal disease (IPD) (http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/). Accessed 31 August 2011.
14.Huang, SS, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Paediatrics. Published online: July 2009. doi:10.1542/peds.2008-3099.
15.De Carvalho Gomes, H, et al. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007. Eurosurveillance 2009; 14(12).
16.Vestrheim, DF, et al. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 2010; 28: 22142221.
17.Harboe, ZB, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010; 28: 26422647.
18.Black, S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Paediatric Infectious Disease Journal 2010; 29: 301303.
19.O'Brien, KL, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. Journal of Infectious Diseases 2007; 196: 12111220.
20.Weinberger, DM, Malley, R, Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet. Published online: 13 April 2011. doi:10.1016/S0140-6736(10)62225-8.
21.Brueggemann, AB, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathogens 2007; 3: 16281636.
22.Trotter, CL, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. Journal of Infection 2010; 60: 200208.
23.Jefferies, JM, et al. Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. Journal of Clinical Microbiology 2010; 48: 8796.
24.Lepoutre, A, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Eurosurveillance 2008; 28(35).
25.Whitney, CG, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003; 348: 17371746.
26.Flasche, S, Slack, M, Miller, E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Eurosurveillance 2011; 16(20).
27.Hammitt, LL, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. Journal of Infectious Diseases 2006; 193: 14871494.

Keywords

Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

  • K. E. CHAPMAN (a1), D. WILSON (a2) and R. GORTON (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed